资源描述：
《辉瑞制药pfizer-201501-advancing differentiated high value products-jp morgan healthcare conference_by_md》由会员上传分享，免费在线阅读，更多相关内容在行业资料-天天文库。
1、辉瑞制药Pfizer-201501-AdvancingDifferentiatedHighValueProducts-JPMorganHealthcareConference_By_MDJPMorganHealthcareConferenceAdvancingDifferentiatedHighValueProductsMikaelDolsten,M.D.,Ph.D.PresidentWorldwideR&DJanuary<#004699'>13,20<#004699'>15Forward-lookingStatements2??T
2、hispresentationincludesforward-lookingstatementsabout,amongotherthings,developmentofPfizer’sproductsandproductcandidates,includingtheirpotentialbenefits,expectedclinicaltrialstudystartsandexpectedregulatorysubmissionsandapprovalsthataresubjecttosubstantialrisksanduncertain
3、tiesthatcouldcauseactualresultstodiffermateriallyfromthoseexpressedorimpliedbysuchstatements.AdditionalinformationregardingthesefactorscanbefoundinPfizer’sAnnualReportonForm<#004699'>10-KforthefiscalyearendedDecember3<#004699'>1,20<#004699'>13andinoursubsequentreportsonFor
4、m<#004699'>10-Q,includinginthesectionsthereofcaptioned“RiskFactors”and“Forward-LookingInformationThatMayAffectFutureResults”,aswellasinoursubsequentreportsonForm8-K,allofwhicharefiledwiththeSECandavailableat.sec.govand.pfizer4>>.Theforward-lookingstatementsinthispresentati
5、onspeakonlyasoftheoriginaldateofthispresentation,andweundertakenoobligationtoupdateorreviseanyofthesestatements.??Also,thediscussionsduringthispresentationmayincludecertainfinancialmeasuresthatwerenotpreparedinaccordancewithU.S.generallyacceptedaccountingprinciples(GAAP).R
6、econciliationsofthosenon-U.S.GAAPfinancialmeasurestothemostdirectlycomparableU.S.GAAPfinancialmeasurescanbefoundinPfizer’sCurrentReportonForm8-KdatedOctober28,20<#004699'>14andPfizer’sQuarterlyReportonForm<#004699'>10-QforthefiscalquarterendedSeptember28,20<#004699'>14.??T
7、hesereportsareavailableonourwebsiteat.pfizer>inthe“Investors–SECFilings”section.NovelLaunchedProductswithUniqueClinicalProfilesRecentApprovalsPfizerPipelineAsofNovember6,20<#004699'>14Phase<#004699'>13586Total2<#004699'>14DiscoveryProjectsPhase222Phase323Registration63Larg
8、e,HighQualityR&DPipelinewithMixofNMEsandNewIndicationsDeliveringNovel&Differentia
